TRAF4 Maintains Deubiquitination of Caveolin-1 to Drive Glioblastoma Stemness and Temozolomide Resistance

Overview

Journal Cancer Res

Specialty Oncology

Date 2022 Jul 27

PMID 35895752

Authors

Yongxu Li

Tiepeng Wang

Quan Wan

Qing Wang

Zhenzhong Chen

Yuan Gao

Yuchen Ye

Jiusheng Lin

Bihuan Zhao

Huaile Wang

Jinming Yang

Kai Zhao

Na Lu

Affiliations

Soon will be listed here.

Abstract

Significance: The identification of a TRAF4/Caveolin-1 axis that plays a crucial role in malignant progression of glioblastoma provides new insights into the function of TRAF4 in ubiquitin signaling and suggests TRAF4 as a potential therapeutic target.

Citing Articles

Nerve Growth Factor Signaling Promotes Nuclear Translocation of TRAF4 to Enhance Tumor Stemness and Metastatic Dormancy Via C-Jun-mediated IL-8 Autocrine.

Zhao K, Sun T, Sun Q, Chen Z, Wang T, Yang J Adv Sci (Weinh). 2024; 12(7):e2414437.

PMID: 39716976 PMC: 11831473. DOI: 10.1002/advs.202414437.

BRD4 Degradation Enhanced Glioma Sensitivity to Temozolomide by Regulating Notch1 via Glu-Modified GSH-Responsive Nanoparticles.

Yi L, Zhang Z, Zhou W, Zhang Y, Hu Y, Guo A Adv Sci (Weinh). 2024; 11(48):e2409753.

PMID: 39544152 PMC: 11672279. DOI: 10.1002/advs.202409753.

High Caveolin-1 mRNA expression in triple-negative breast cancer is associated with an aggressive tumor microenvironment, chemoresistance, and poor clinical outcome.

Godina C, Khazaei S, Belting M, Vallon-Christersson J, Nodin B, Jirstrom K PLoS One. 2024; 19(7):e0305222.

PMID: 38959243 PMC: 11221642. DOI: 10.1371/journal.pone.0305222.

Drug resistance mechanisms and treatment strategies mediated by Ubiquitin-Specific Proteases (USPs) in cancers: new directions and therapeutic options.

Gao H, Xi Z, Dai J, Xue J, Guan X, Zhao L Mol Cancer. 2024; 23(1):88.

PMID: 38702734 PMC: 11067278. DOI: 10.1186/s12943-024-02005-y.

Oxyberberine sensitizes liver cancer cells to sorafenib via inhibiting NOTCH1-USP7-c-Myc pathway.

Sun L, He M, Li F, Wu D, Zheng P, Zhang C Hepatol Commun. 2024; 8(4).

PMID: 38573832 PMC: 10997235. DOI: 10.1097/HC9.0000000000000405.